Abstracts tagged "Biomarkers"

Abstract Number: 307 • 2013 ACR/ARHP Annual Meeting
Abnormal Imaging and Increased Osteoclast Precursors In a Psoriasis Cohort Are Associated with New Onset of Psoriatic Arthritis
Ralf G. Thiele¹, Yahui Grace Chiu¹, Francisco A. Tausk², Bethany A. Marston¹, Gregory Dieudonne³, Vaseem Chengazi³, Michelle Smith¹, Sharon Moorehead¹, Rick Barrett¹ and Christopher T. Ritchlin¹, ¹Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ²Dermatology, University of Rochester, Rochester, NY, ³Radiology, University of Rochester, Rochester, NY
Background/Purpose: Psoriasis (Ps) precedes joint inflammation by about 10 years in patients who develop psoriatic arthritis (PsA). Several studies have documented abnormal musculoskeletal imaging findings…
Abstract Number: 70 • 2013 ACR/ARHP Annual Meeting
Chondrocyte Hypertrophy, Measured By The Secretion Of Collagen Type X, Is Associated With Cartilage Degradation and Systemic Inflammation In Osteoarthritis
Yi He¹, Natasja Stæhr Gudman², Niels Ulrik Hansen¹, Jianxia Wang³, Di Su⁴, Qinlong Zheng⁴, Ole Simonsen⁵, Kristian Kjaer Petersen⁶, Moustapha Kassem⁷, Morten Asser Karsdal² and Anne C. Bay-Jensen⁸, ¹Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Cartilage biology and biomarkers, Nordic Bioscience China, Beijing, China, ⁴Nordic Bioscience China, Beijing, China, ⁵Frederikshavn Hospital, Frederikshavn, Denmark, ⁶Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Denmark, Center for Sensory-Motor Interaction, Aalborg, Denmark, ⁷Department of Endocrinology and Metabolism, Odense University Hospital and University of Southern, Odense, Denmark, ⁸Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Osteoarthritis (OA) is the most common degenerative joint disease, of which the pathogenesis is inadequately understood. The hypertrophy-like changes, such as expression of hypertrophy…
Abstract Number: 2288 • 2013 ACR/ARHP Annual Meeting
Novel Biomarkers From Peripheral Blood Mononuclear Cells Indicate Disease Activity In Rheumatoid Arthritis Patients
Jason Ptacek¹, Rachael Hawtin², Brent Louie¹, Erik Evensen¹, James Cordeiro¹, Barbara Mittleman¹, Michelle Atallah¹, Alessandra Cesano², Clifton O. Bingham III³, Stacey Cofield⁴, Jeffrey R. Curtis⁵, Maria I. Danila⁴, Richard A. Furie⁶, MC Genovese⁷, Marc C. Levesque⁸, Larry W. Moreland⁸, Peter A. Nigrovic⁹, James R. O'Dell¹⁰, William H. Robinson¹¹, Nancy A. Shadick⁹, E. William St Clair¹², Christopher C. Striebich¹³, Geoffrey M Thiele¹⁴, Peter K. Gregersen⁶ and S. Louis Bridges Jr.⁴, ¹Nodality, Inc., South San Francisco, CA, ²Nodality Inc., South San Francisco, CA, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, School of Public Health, Birmingham, AL, ⁶The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ⁷Stanford University, Palo Alto, CA, ⁸University of Pittsburgh, Pittsburgh, PA, ⁹Brigham and Women's Hospital/Harvard University, Cambridge, MA, ¹⁰Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ¹¹VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ¹²Medicine, Duke Unversity Medical Center, Durham, NC, ¹³University of Colorado Denver, Aurora, CO, ¹⁴Omaha VA and the University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Biomarkers reflecting immune function and associating with disease activity can help stratify rheumatoid arthritis (RA) patients (pts) in practice and in clinical trials.…
Abstract Number: 1865 • 2013 ACR/ARHP Annual Meeting
Complement Activation and Anaphylatoxin Generation In Response To Staphylococcal Protein A Exposure: Ex Vivo and In Vivo Human Studies
Edward Bernton¹, Antonio Polley², Susan Zondlo², Lynne Mitchell³ and Dennis Hourcade³, ¹Protalex Inc., Summit, NJ, ²QPS Holdings LLC, Newark, DE, ³Division of Rheumatology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: PRTX-100, a highly-purified GMP staphylococcal protein A (SpA), is currently in clinical trials treating patients with active rheumatoid arthritis (RA). It has been reported…
Abstract Number: 1274 • 2013 ACR/ARHP Annual Meeting
Maternal Vitamin D, Fetal C-Reactive Protein and Brain Natriuretic Peptide Associate With The Development and Morbidity Of Cardiac Neonatal Lupus
Amit Saxena¹, Peter M. Izmirly², Joanne H. Reed³, Sara Sahl², Deborah Friedman⁴, Robert M. Clancy³ and Jill P. Buyon², ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴Division of Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: Women with anti-Ro antibodies face the risk of having a child with cardiac Neonatal Lupus (NL), characterized by congenital heart block and/or cardiomyopathy. Biomarkers…
Abstract Number: 313 • 2013 ACR/ARHP Annual Meeting
The DC-STAMP⁺IL17A⁺ Cell Subset Is Elevated In Psoriatic Arthritis (PsA) Patients and Declines Following Anti-TNFi Therapy
Yahui Grace Chiu¹, Edward M. Schwarz², Hua He³, Francisco A. Tausk⁴, Sharon Moorehead⁵, Michelle Smith⁵ and Christopher T. Ritchlin⁵, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ³Biostatistics and Computational Biology, University of Rochester, Rochester, NY, ⁴Dermatology, University of Rochester, Rochester, NY, ⁵Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Approximately 25% of psoriasis (Ps) patients develop psoriatic arthritis (PsA), a potentially destructive joint disease, within 10 years of Ps onset. Although early diagnosis…
Abstract Number: 71 • 2013 ACR/ARHP Annual Meeting
Subchondral Bone Turnover and Osteophyte Formation Are Key Aspects In The Progression Of Osteoarthritis and May Be Assessed and Predicted By a-CTX
Morten Asser Karsdal¹, Janet L. Huebner², Virginia Byers Kraus², Diana J. Leeming¹, Edward Coleman², Gary E. McDaniel³, Kim M. Huffman³, Kim Henriksen¹ and Anne C. Bay-jensen¹, ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Medicine/Rheumatology, Duke University Medical Center, Durham, NC, ³Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritic disease. It is characterized by pathological changes in both bone and cartilage turnover as well…
Abstract Number: 2263 • 2013 ACR/ARHP Annual Meeting
ADAMTS5 Is a Biomarker For The Efficacy Prediction Of Tocilizumab In Rheumatoid Arthritis
Kensei Tsuzaka, Masako Takao and Jiro Nishida, Dept of Internal Medicine, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan
a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) mRNA level. In this study presented here, we investigated whether the efficacy of tocilizumab (TCZ) for…
Abstract Number: 1845 • 2013 ACR/ARHP Annual Meeting
Soluble Type I Interferon Receptor 2 Is Elevated By Interferon Treatment and In Certain Autoimmune Diseases
Taher Fatakdawala¹, Michael Skawinski¹, Jonathan Ferriera², Tara Stauffer¹ and Thomas Lavoie¹, ¹Product Research & Development and Assay Services, PBL Assay Science, Piscataway, NJ, ²Quality Control, PBL Assay Science, Piscataway, NJ
Background/Purpose: The Type I Interferon (IFN) receptor is a heterodimer of chain 1 (IFNAR1) which is required for signaling, and chain 2 (IFNAR2) which binds…
Abstract Number: 1250 • 2013 ACR/ARHP Annual Meeting
Serological Markers Of Structural Integrity and Inflammation Is Associated With Pain In Osteoarthritis
Anne Sofie Siebuhr¹, Lars Arendt-Nielsen², Thomas Navndrup Eskehave³, Morten Asser Karsdal⁴, Kristian Kjaer Petersen⁵, Ole Simonsen⁶ and Anne C. Bay-Jensen⁷, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Center for Sensory-Motor Interaction, Aalborg, Denmark, ³Center for Clinical and Basic Research and C4Pain, Aalborg, Denmark, ⁴Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ⁵Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Denmark, Center for Sensory-Motor Interaction, Aalborg, Denmark, ⁶Frederikshavn Hospital, Frederikshavn, Denmark, ⁷Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark
Background/Purpose: Pain is associated with diagnosed osteoarthritis (OA), but little clinically association is found between joint integrity and the pain the individual patient experience. Peripheral…
Abstract Number: 245 • 2013 ACR/ARHP Annual Meeting
C-Reactive Protein But Not Erythrocyte Sedimentation Rate Is Associated With Decrease In Muscle Strength In Patients With Knee Osteoarthritis: A 2 Year Follow Up Study
Diana C Sanchez-Ramirez¹, Marike van der Leeden², Martin van der Esch³, Leo D. Roorda², Sabine Verschueren⁴, Jaap van Dieen⁵, Joost Dekker⁶ and Willem F. Lems⁷, ¹Human movement sciences, VU university Amsterdam, Amsterdam, Netherlands, ²Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, ³Amsterdam Rehabilitation Research Center, Reade, Amsterdam, Netherlands, ⁴Department of Rehabilitation Sciences, KU University of Leuven, Leuven, Belgium, ⁵Faculty of Human Movement Sciences, VU University, Amsterdam, Netherlands, ⁶Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, ⁷Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: In patients with knee osteoarthritis activity limitations and disease progression have been associated with muscle weakness (OA). Muscle weakness might be determined by factors…
Abstract Number: 2902 • 2013 ACR/ARHP Annual Meeting
Key Roles For Interferon and Macrophage Activation In Progressive Lung Fibrosis Associated With Systemic Sclerosis
Romy Christmann¹, Giuseppina Stifano², Claudia Borges³, Carlos Carvalho⁴, Ronaldo Kairalla⁴, Edwin R. Parra⁵, Avrum Spira⁶, Robert W. Simms¹, Percival Sampaio-Barros⁷, Vera L. Capelozzi⁵ and Robert Lafyatis¹, ¹Rheumatology, Boston University School of Medicine, Boston, MA, ²Rheumatology, Boston University Medical Center, Boston, MA, ³Rheumatology, CEUMA University, Sao Luis do Maranhao, Brazil, ⁴Pulmonology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, ⁵Pathology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, ⁶Computational Biomedicine, Boston University School of Medicine, Boston, MA, ⁷Rheumatology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
Background/Purpose: Interstitial lung disease associate with Systemic Sclerosis(SSc-ILD) is one of the leading causes of mortality. We analyzed the gene expression of lung tissue in…
Abstract Number: 2262 • 2013 ACR/ARHP Annual Meeting
Antibody To Malondialdehyde-Acetaldehyde Adducts (MAA) Is a Biomarker Of Inflammation and Is Correlated With The Disease Activity In Rheumatoid Arthritis
Kathleen Young¹, Dathe Benissan-Messan², Michael J. Duryee³, Daniel Anderson⁴, Liron Caplan^5,6, Lisa A. Davis^7,8,9, Harlan Sayles⁴, Carlos D. Hunter³, Lynell W. Klassen¹⁰, James R. O'Dell¹¹, Ted R. Mikuls⁴ and Geoffrey M Thiele¹², ¹Int Med/Sec of Rheum/Immun, University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Department of Medicine, Denver Veterans Affairs Medical Center, Denver, CO, ⁶Department of Medicine, University of Colorado School of Medicine, Aurora, CO, ⁷Division of Rheumatology, Univ. of Colorado Sch. of Medicine, Aurora, CO, ⁸Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁹Denver Veterans Affairs Medical Center, Denver, CO, ¹⁰Dept of Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ¹¹Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ¹²Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with rheumatoid arthritis (RA). While there are many markers used…
Abstract Number: 1809 • 2013 ACR/ARHP Annual Meeting
Topline Results Of The Biomarkers Of Lupus Disease (BOLD) Study: Clinical and Mechanistic Perplexities Of Lupus Treatment Trials Can Be Mitigated By Eliminating Background Immune Suppressants
Joan T. Merrill¹, Frederick W. Immermann², Tianhui Zhou³, Margot O'Toole⁴, Maryann Whitley⁵, Andrew A. Hill⁵, Ying Zhang⁵, David von Schack⁵, Padmalatha S. Reddy⁵, Jaime L. Masferrer⁴, Stan Kamp¹, Joel M. Guthridge⁶, Aikaterini Thanou⁷, Paul Wu⁵, Theresa Paradis⁵, William M. Mounts⁵, Judith A. James⁸ and Sudhakar T. Sridharan², ¹Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²BioTherapeutics R&D, Pfizer Inc, Collegeville, PA, ³BioTherapeutics R&D, Bristol Myers Squibb, Princeton, NJ, ⁴independent consultant, Cambridge, MA, ⁵Pfizer Inc, Cambridge, MA, ⁶Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Arthritis and Clinical Immmunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The BOLD study was designed to test the discriminatory capacity and safety of a trial design eliminating background immune suppressants (IS) in SLE patients…
Abstract Number: 1253 • 2013 ACR/ARHP Annual Meeting
Studies On The Relationship Between Intraplantar Carrageenan-Induced Bradykin B1 Receptor Messenger Ribonucleic Acid Expression and Oedema and Hyperalgesia In Rats: Effects Of Dexamethasone and a B1 Receptor Antagonist, BI-113823
Guy Kennett¹, Jessica Arlott¹, Phil Butler², Mike Comer¹, Andrew Clarkson², Alex Coulthard¹, Sean Lightowler¹, Rachel Upcott-Gill², Rebecca Upton¹, Louise Wray², Philipp Wabnitz³, Sven Kühnert³ and Simon Cruwys³, ¹Saretius Ltd, Reading, United Kingdom, ²Cyprotex Ltd, Macclesfield, United Kingdom, ³Grunenthal GmbH, Aachen, Germany
Background/Purpose: Kinins are a group of peptides formed in plasma and tissues in response to infection, tissue trauma or inflammation (inflamm) whose actions are mediated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].